Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium☆
References (18)
- et al.
Progesterone binding in human endometrial adenocarcinomas
Am J Obstet Gynecol
(1976) - et al.
The effect of estrogen receptor status on survival in patients with endometrial cancer
Am J Obstet Gynecol
(1983) - et al.
Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria. Therapeutic implications
Am J Obstet Gynecol
(1981) - et al.
Endometrial carcinoma: Steroid receptors and response to medroxyprogesterone acetate
Gynecol Oncol
(1985) - et al.
Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma
Am J Obstet Gynecol
(1985) - et al.
Role of steroid hormone receptors as prognostic factors in primary breast cancer
Natl Cancer Inst Monogr
(1986) Endometrial cancer. The emergence of therapeutic individualization
Prog Gynecol
(1983)- et al.
Management of endometrial adenocarcinoma stage I with surgical staging followed by tailored adjuvant radiation therapy
Clin Obstet Gynecol
(1986) - et al.
Do estrogen and progesterone receptors (E2R and PR) in metastasizing endometrial cancers predict the response to gestagen therapy
Acta Obstet Gynecol Scand
(1980)
There are more references available in the full text version of this article.
Cited by (185)
Reproductive advance of fertility preservation in patients with early endometrial carcinoma or endometrial atypical hyperplasia
2022, Gynecology and Obstetrics Clinical MedicineEstrogen Inhibits Epithelial Progesterone Receptor–Dependent Progestin Therapy Efficacy in a Mouse Model of Cervical Cancer
2022, American Journal of PathologyChinese expert consensus on fertility-preserving treatment for young women with early stage well differentiated endometrial cancer
2021, Gynecology and Obstetrics Clinical MedicineEndometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II
2021, Gynecologic OncologyMedroxyprogesterone Acetate Prevention of Cervical Cancer through Progesterone Receptor in a Human Papillomavirus Transgenic Mouse Model
2019, American Journal of PathologyCitation Excerpt :It is intriguing that one HPVtg/Pgr−/− mouse treated with MPA had a hypoplastic epithelium without any cervical neoplastic disease (Figure 4B and Supplemental Figure S2A). Some PR-negative endometrial cancers respond to MPA therapy.39,52 These observations suggest that MPA may be useful in preventing cervical cancer through a PR-independent mechanism under conditions yet to be determined.
Hormone-Responsive Cancers
2019, Yen & Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management: Eighth Edition
- ☆
Presented at the Sixth Annual Meeting of the American Gynecological and Obstetrical Society, Phoenix, Arizona, September 10–12 1987.
Copyright © 1988 Published by Mosby, Inc.